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Abstract
Pentachlorophenol (PCP) and Dichlorodiphenyltrichloroethane (DDT) are environmental 
contaminants found in human blood. Previous studies have shown that PCP and DDT inhibit the 
lytic function of highly purified human natural killer (NK) lymphocytes and decrease the 
expression of several surface proteins on NK cells. Interleukin-1 βeta (IL-1β) is a cytokine 
produced by lymphocytes and monocytes and anything that elevates its levels inappropriately can 
lead to chronic inflammation, which among other consequences can increase tumor development 
and invasiveness. Here PCP and DDT were examined for their ability to alter secretion of IL-1β 
from immune cell preparations of various complexity: NK cells; monocyte depleted (MD) 
peripheral blood mononuclear cells (PBMCS), and PBMCs. Cells were exposed to concentrations 
of PCP ranging from 5 µM to 0.05 µM and DDT concentrations of 2.5µM to 0.025µM for 24 h, 48 
h and 6 days. Results showed that both PCP and DDT increased IL-1β secretion from all of the 
immune cell preparations. The specific concentrations of PCP and DDT that increased IL-1β 
secretion varied by donor. Immune cells from all donors showed compound-induced increases in 
IL-1β secretion at one or more concentration at one or more length of exposure. The mechanism 
of PCP stimulation of IL1-β secretion was also addressed and it appears that the MAPKs, ERK1/2 
and p38, may be utilized by PCP to stimulate secretion of IL-1β.
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INTRODUCTION
IL-1β is one of the most powerful pro-inflammatory cytokines; it affects virtually every 
organ, and several human pathologies are primarily driven by unrestrained IL-1β production. 
Over production contributes to pathophysiological changes seen in diseases such as 
rheumatoid arthritis, neuropathic pain, inflammatory bowel disease, osteoarthritis, vascular 
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disease, multiple sclerosis, Alzheimer’s disease, and cancer (Dinarello, 1996; Braddock & 
Quinn, 2004; Dinarello, 2004; Coussens & Werb, 2002). IL-1β exerts its protective action 
against infections by activating several responses including the rapid recruitment of 
neutrophils to inflammatory sites, activation of the endothelial adhesion molecules, 
induction of cytokines and chemokines, and the stimulation of adaptive immunity. (Sahoo et 
al., 2011). IL-1β is produced by several different categories of immune cells including 
monocytes (Shi & Pamer, 2011), T cells (Numerof et al., 1990) and natural killer (NK) cells 
(De Sanctis et al., 1997). IL-1β is secreted in response to immune cell recognition of 
pathogen associated molecular patterns (PAMPs) through pattern recognition receptors 
(PRR) (Gaestel et al. 2009). Pro IL-1β matures to IL-1β by interacting with the protease, 
caspase 1 (Lopez-Castejon & Brough, 2011; Swaan et al., 2001; Dinarello, 1996). Caspase 1 
is activated by an intracellular multiprotein complex referred to as the inflammasome. It 
cleaves the 31 kD pro IL-1β to the mature 17 kD form leading to its secretion (Church et al., 
2008; Franchi et al., 2009; Lopez-Castejon & Brough, 2011; Martinon & Tschopp, 2007). A 
favorable environment for angiogenesis and metastasis results when chronic inflammation 
provides an abundant source of growth factors, cytokines, chemokines, prostaglandins, and 
reactive oxygen species (Balkwill & Mantovani 2001; Coussens & Werb, 2002). 
Inflammation and dysregulation in immune cells could be caused by exposure to 
environmental contaminants that are found in human blood.
Pentachlorophenol (PCP) is an organochlorine compound that contaminates the environment 
due to its various uses (ATSDR, 2001; Cirelli, 1978; Brown et al., 2005). PCP has been used 
as a fungicide, insecticide, herbicide, in antifouling paint, and as a wood preservative 
(Cirelli, 1978). It has been found in human blood with serum levels ranging from 0.26 −5 
µM in individuals who live in PCP-treated log homes (Cline et al., 1989). Levels averaging 
0.15 µM were found in the serum of individuals with no known exposure (Cline et al., 1989; 
Uhl et al., 1986). PCP exposure is associated with cancers of the blood (lymphoma and 
myeloma) and kidney (Demers et al., 2006; Cooper & Jones, 2008). Cytotoxic and gene 
expression effects of PCP in human liver and bladder cells were investigated by Wang et al. 
(2000). Liver cells were more resistant to the toxicity of PCP than were bladder cells and 
expression of cellular apoptosis susceptibility protein (CAS) decreased in cells after 
treatment with PCP.
4, 4′-Dichlorodiphenyltrichloroethane (DDT) was extensively used as an agricultural 
pesticide throughout the world (CDC 2003; 2005; Geisz et al., 2008; Turusov et al., 2002; 
Loganathan, 2012). While it has been banned in many countries including the USA, it is still 
used in other countries primarily to control mosquitos (CDC 2003;2005). Despite its ban, 
DDT has been found in human bodily fluid and has been detected in measurable 
concentrations in blood samples within the US population (Thornton et al., 2002; Patterson 
et al., 2009). In countries such as Mexico where DDT is still used, it has been found in 
serum with concentrations as high as 23,169 ng/g of lipid (approximately 260 nM) (Koepke 
et al., 2004; Trejo-Acevedo et al., 2009). An association between blood levels of DDT and 
decreased numbers of NK cells as well as decreased NK function has been reported 
(Svensson et al., 1994; Eskenazi et al., 2009).
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Results of prior ex vivo studies indicate that exposure of human NK cells to both PCP and 
DDT causes inhibition of their ability to bind and lyse tumor target cells (Reed et al., 2004; 
Nnodu and Whalen, 2008; Udoji et al., 2010; Hurd et al., 2012; Hurd-Brown et al., 2013). 
Both compounds also decrease the expression of certain cell-surface proteins needed for NK 
lymphocytes to bind to tumor targets (Hurd et al., 2012; Hurd-Brown et al., 2013). 
Dysregulation in secretion of NK-stimulatory ILs (IL-2, IL-12 and/or IL-10) and NK-
inhibitory cytokine, IL-4 has been reported after exposure to PCP and DDT (Beach & 
Whalen, 2006). Based on the results from previous studies on the effects of PCP and DDT 
on immune function and the importance of IL-1β as a master regulator of immune response 
and inflammation, we hypothesize that PCP and DDT may alter the secretion of IL-1β from 
human immune cells.
In this study, preparations of immune cells with increasing complexity were utilized to 
investigate the effects of ex vivo exposures to PCP and DDT on the secretion of IL-1β. 
Human NK cells, human monocyte-depleted (MD) peripheral blood mononuclear cells 
(PBMCs) (MD-PBMCs), and PBMCs were each exposed to the compounds and secreted 
IL-1β levels were assessed. Monitoring exposure to PCP and DDT on these increasingly 
reconstituted preparations of immune cells allows us to see whether the effects of the 
compounds are dependent on the nature of the cell preparation. An additional goal of this 
study was to investigate the mechanism of any compound-induced increases in IL-1β 
secretion. Thus, additional studies were done where PBMCs were pre-treated with 
Caspase-1 inhibitor, p44/42 (ERK 1/2) pathway inhibitor, JNK pathway inhibitor, p38 
inhibitor, or NFĸB inhibitor before exposure to the compounds.
MATERIALS AND METHODS
Preparation of PBMCs, and Monocyte Depletion- PBMCs
PBMCs were isolated from leukocyte filters (PALL-RCPL or FLEX) obtained from the Red 
Cross Blood Bank (Nashville, TN) as described in (Meyer et al., 2005). Leukocytes were 
obtained from the filters by back-flushing the filters with an elution medium which contains 
(sterile phosphate buffered saline (PBS) containing 5 mM disodium EDTA and 2.5% [w/v] 
sucrose) and then collecting the eluent. The eluent was layered onto LymphoSep cell 
separation medium (1.077g/mL) (MP Biomedicals, Irvine, CA) and centrifuged at 1200g for 
30–50 min. Following centrifuging and washing, the cells were layered on bovine calf serum 
for platelet removal. The cells were then suspended in RPMI-1640 complete medium which 
consisted of RPMI-1640 supplemented with 10% heat-inactivated BCS, 2 mM L-glutamine 
and 50 U penicillin G with 50 µg streptomycin/mL Monocyte-depleted (MD) PBMCs (10–
20% CD16+, 10–20 % CD56+, 70–80% CD3+, 3–5% CD19+, 2–20% CD14+) were prepared 
by incubating PBMCs in glass Petri dishes (150 × 15 mm) at 37 °C and air/CO2, 19:1 for 1 
h.
Preparation of NK cells
NK cells were isolated from buffy coats (source leukocytes from healthy adult donors) 
purchased from Key Biologics, LLC (Memphis, TN) using a rosetting procedure. 
RosetteSep human NK cell enrichment antibody cocktail (0.6–0.8 mL) (StemCell 
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Technologies, Vancouver, British Columbia, Canada) was added to 45 mL of the buffy coat. 
The mixture was incubated for 20 min at room temperature (~ 25° C). Eight mL of the 
mixture was layered onto 4 mL of LymphoSep (1.077 g/mL) and centrifuged at 1200 g for 
30–50 min. The NK cells were collected and washed twice with phosphate buffered saline 
(PBS) pH 7.4 and stored in complete media (RPMI-1640 supplemented with 10% heat-
inactivated bovine calf serum (BCS), 2 mM L-glutamine and 50 U penicillin G with 50 µg 
streptomycin/ml) at 1 million cells/mL at 37 °C and air/CO2, 19:1.
Chemical Preparation
DDT and PCP were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions were 
prepared as 100 mM solutions in Dimethylsulfoxide (DMSO). Desired concentrations of 
either DDT or PCP were prepared by dilution of the desired stock into cell culture media.
Inhibitor Preparation
Enzyme inhibitors were purchased from Fisher Scientific (Pittsburgh, PA).The stock solution 
for each inhibitor was a 50 mM solution in dimethylsulfoxide (DMSO). Capase-1 inhibitor 
II, MEK 1/2 pathway inhibitor (PD98059), p38 inhibitor (SB202190), JNK inhibitor 
(B178D3), and NFκB inhibitor (BAY11–7085) were prepared by dilution of the stock 
solution into cell culture media.
Cell Treatments
PBMCs, MD-PBMCs, and NK cells (at a concentration of 1.5 million cells/ mL) were 
treated with PCP (0.05–5 µM) and appropriate control for 24 h, 48 h, and 6 days. 
Additionally, each of the above types of cell preparations were treated with DDT (0.025–2.5 
µM) and appropriate control for 24h, 48h, and 6 days. Once the incubation period was 
complete, the cells were pelleted and supernatants were obtained and stored at −70 C until 
assaying for IL-1β. For the pathway inhibitor experiments, PBMCs were treated with 
enzyme inhibitors 1 h prior to adding PCP at concentrations of 5, 2.5, and 1 µM for 24 h. 
After the cells were incubated, the cells were pelleted and supernatants were obtained and 
stored at −70 C until assaying for IL-1β.
Cell Viability
Cell viability was measured at the end of the 24 h, 48 h and 6 day exposure period. Viability 
was determined using the trypan blue exclusion method. Cells were mixed with trypan blue 
and counted using a hemocytometer. The total number of cells and the number of dead were 
counted for both control and treated cells to determine the percent viable cells.
IL-1β Secretion Assay
IL-1β levels were measured using the BD OptEIA™ Human IL-1β enzyme-linked 
immunosorbent assay (ELISA) kit (BD-Pharmingen, San Diego, CA). A 96-well micro well 
plate, designed for ELISA assays (Fisher, Pittsburgh, PA), was coated with a capture 
antibody for IL-1β that was diluted in coating buffer. The ELISA plate was incubated with 
the capture antibody overnight at 4 °C. After the incubation, the capture antibody was 
removed and blocking solution (PBS and bovine calf serum) was added to each well and 
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incubated at room temperature for 1h. Following the blocking step, cell supernatants and 
IL-1β standards were added to the and incubated for 2 h at room temperature. Detection 
antibody linked to horseradish peroxidase (HRP) was then added followed by substrate. The 
reaction was stopped by addition of 1 M phosphoric acid and absorbance was measured at 
450 nm on a Thermo Labsystems Multiskan MCC/340 plate reader (Fisher Scientific).
Statistical Analysis
Data was analyzed using ANOVA and the Student’s t test. Data were initially compared 
within a given experimental setup by ANOVA. A significant ANOVA was followed by pair 
wise analysis of control versus exposed data using Student’s t test, a p value of less than 0.05 
was considered significant.
RESULTS
Viability of NK cells, MD-PBMCs, and PBMCs exposed to PCP
Exposures to PCP (0.05–5 µM) for 24 h and 48 h had no effect on the viability of NK cells, 
MD-PBMCs, and PBMCs. Exposures of NK cells and PBMCs to these same concentrations 
of PCP for 6 d also caused no decreases in viability when compared to control cells (data not 
shown). However MD-PBMCs showed a small but significant decrease in viability with 
exposures to 1µM (13% decrease) and 5µM PCP (7% decrease) after 6 days.
Viability of NK cells, MD-PBMCs, and PBMCs exposed to DDT
Exposure of NK cells, MD-PBMCs, and PBMCs to 0.025–2.5 µM DDT for 24 h, 48 h, or 6 
d produced no significant decreases in cell viability as compared to the control (data not 
shown).
Viability of PBMCs treated with selective enzyme inhibitors and then exposed to PCP
PBMCs pre-treated for 1 h with selected signaling pathway inhibitors followed by exposure 
to 1, 2.5, or 5 µM PCP for 24 h were also examined for viability. There were no significant 
changes in the viability of these cells compared to appropriate controls with any of the 
inhibitors (data not shown).
Effects of PCP Exposures on Secretion of IL-1β by NK cells
Table 1 shows the effects on IL-1β secretion by NK cells exposed to 0, 0.05, 0.1, 0.25, 0.5, 
1, 2.5, and 5 µM PCP for 24 h, 48 h, and 6 days. Cells from 4 donors were tested. IL-1β 
secretion from NK cells of donor KB188 (KB=Key Biologic buffy coat) was increased by 
1.3 fold when the cells were exposed to 2.5 µM PCP for 24 h (p<0.05). IL-1β secretion was 
not significantly increased at this same concentration in cells from the other 3 donors and 
was significantly decreased at the 5 µM exposure after 24 h. 48 h exposures to one or more 
concentration of PCP caused increases in IL-1β secretion in cells from 3 of the 4 donors 
(KB188, 192, 194). NK cells from donor KB196 showed increased secretion of IL-β with 
0.05 and 0.1 µM exposures to PCP after 6 days. Thus, all donor NK cells showed increased 
secretion of IL-1β after exposure to PCP, however, the concentrations and lengths of 
exposure at which these increases occurred varied among the donors.
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Effects of PCP Exposures on Secretion of IL-1β by MD-PBMCs
The effects of exposures to PCP on secretion of IL-1β from MD-PBMCs after 24 h, 48 h, 
and 6 d from 4 donors (F=filter obtained from the Red Cross) are shown in Table 2. This 
preparation consists mainly of NK cells and T cells. When MD-PBMCs were exposed to 
PCP for 24 h, there were statistically significant increases in IL-1β secretion at the 5 µM 
concentration of PCP for all donors. The fold increases were 1.7 fold for F209, 1.8 fold for 
F239, 2.5 fold for F241, and 2 fold for F243 when compared to the control. All but one of 
the donors showed increased secretion at other concentrations as well, but the concentration 
at which these increases occurred varied among the donors. The results after 48 h and 6 d of 
exposure to PCP were similar to those seen after 24 h. Results from a representative 
experiment are shown in Figure 1A.
Effects of PCP Exposures on Secretion of IL-1β PBMCs
Table 3 shows the results of exposing PBMCs from 4 individual donors to 0–5 µM, PCP for 
24 h, 48 h, and 6 d on the secretion of IL-1β. When PBMCs were exposed to PCP for 24 h, 
there were statistically significant increases in IL-1β secretion induced at 5 µM and 1 µM 
concentrations of PCP for all donors. The fold increases were 2.7 (F197), 2.2 (F211), 2.6 
(F214), and 13 (F238) at 5 µM PCP compared to the secretion levels of the control after 24 
hours. The effects of 48 h and 6 d exposure to PCP were similar to those seen at 24 h. Figure 
1B shows the results from a representative experiment at all three time points.
Effects of DDT Exposures on Secretion of IL-1β by NK cells
The results of exposing NK cells to 0, 0.025,.05 0.1, 0.25, 0.5, 1,, and 2.5 µM DDT for 24 h, 
48 h, and 6 d on the secretion of IL-1β are summarized in Table 4. 24 h exposures to DDT 
caused significant increases in IL-1β secretion from NK cells of 3 of the 4 donors, while the 
fourth donor was unaffected by exposures. However, after 48 h the donor that had shown no 
significant increases in IL-1β secretion at 24 h now showed a 1.5 fold increase when 
exposed to 1 µM DDT. Thus, all donors showed an increase in IL-1β secretion after 
exposure to at least one concentration of DDT within 48 h.
Effects of DDT Exposures on Secretion of IL-1β by MD-PBMCs
Table 5 shows the effects of exposing MD-PBMCs from 4 individual donors to 0 – 2.5 µM 
DDT for 24 h, 48 h, and 6 d on the secretion of IL-1β. Significant increases (2 fold) in IL-1β 
secretion were shown in three donors, at 2.5 µM (F245, F281, F288). Significant decreases 
in IL-1β secretion were seen at several DDT concentrations in donor F287. At 48 h, all 
donors exhibited increased IL-1β secretion with exposure to at least on concentration of 
DDT. 6d exposures to DDT showed effects similar to those seen at 48 h. Figure 2A shows 
the effects of 24 h, 48 h, and 6 d exposures of MD-PBMCs to DDT from a representative 
donor.
Effects of DDT Exposures on Secretion of IL-1β by PBMCs
The effects of exposing PBMCs from 5 individual donors to 0, 0.025, .05 0.1, 0.25, 0.5, 1, 
and 2. 5 µM DDT for 24 h, 48 h, and 6 d on the secretion of IL-1β are shown in Table 6. At 
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48 h of exposure to DDT, all donors showed a significant increase in IL-1β secretion at the 
2.5 µM concentration. Results from a representative donor are shown in Figure 2B.
Effects of PCP Exposures on Secretion of IL-1βeta by PBMCS treated with Selective 
Enzyme Inhibitors
NFκB Inhibitor (BAY 11-7085)—The effects of exposures to 1, 2.5 and 5 µM PCP on 
secretion of IL-1β from PBMCs where NFκB was inhibited with BAY 11–7085 (0.325 µM) 
are shown in Table 7. In some donors inhibition of the NFκB pathway slightly increased the 
ability of PCP to stimulate IL-1β secretion from PBMCs and in other donors slightly 
decreased the effect of PCP. For instance cells from donor F317 show 9, 7, and 3 fold 
increases when PBMCs are exposed to 5, 2.5, and 1µM PCP in the absence of the NFκB 
inhibitor. When the inhibitor is present PCP exposures result in 7, 5 and 1 fold increases in 
IL-1β secretion. These results suggest that NFκB may play a small role in PCP’s ability to 
stimulate the secretion of IL-1β by PBMCs. Data from a representative experiment are 
shown in Figure 3A.
Mitogen activated protein kinase kinase for ERK1/2 (MEK) Inhibitor (PD98059)
—PCP-induced stimulation of IL-1β secretion in PBMCs pre-treated with the MEK 
inhibitor PD98059 (50 µM) is shown in Table 7. Cells from all donors exposed to 5 µM PCP 
showed increases in IL-1β secretion. This PCP-stimulated secretion was diminished in each 
donor when the ERK1/2 pathway was inhibited by PD98059. There was a decrease in PCP-
stimulated IL-1β secretion at 2.5 and 1 µM PCP in most donors For instance cells from 
donor F320 showed 10, 7.6 and 4.1 fold increases with 5, 2.5, and 1µM in the absence of the 
MEK inhibitor. With the MEK inhibitor, these same concentrations of PCP caused increases 
of only 2.4, 2.6, and 1.6 fold. These results indicate that the ERK1/2 pathway may play a 
significant role in PCP’s ability to stimulate secretion of IL-1β in PBMCs (Figure 3B).
p38 Inhibitor (SB202190)—Table 7 also shows the effects of exposures to 1, 2.5 and 5 
µM PCP on secretion of IL-1β from PBMCs where p38 has been inhibited with SB202190. 
Inhibition of p38 tended to greatly decrease or completely block the PCP-induced increases 
in secretion of IL-1β. Figure 3C (representative data from F319) shows 2.5, 1.8 and 1.4 fold 
increases when PBMCs are exposed to 1, 2.5 and 5 µM PCP in the absence of p38 inhibitor. 
When the inhibitor is present, these same PCP exposures result in a complete block in IL-1β 
secretion. Thus, the p38 MAPK pathway appears to be very important in PCP-stimulated 
IL-1β secretion.
JNK Inhibitor (BI78D3)—The effects of exposures to 1, 2.5 and 5 µM PCP on secretion 
of IL-1β from PBMCs where JNK is inhibited by BI78D3 (0.05 µM) are shown in Table 7. 
Cells exposed to PCP showed similar levels of IL-1β secretion in the presence and absence 
of the JNK inhibitor. This indicates that JNK is not needed for PCP to increase IL-1β 
secretion from PBMCs (Figure 3D).
Caspase 1 Inhibitor—The results of exposures to 1, 2.5 and 5 µM PCP on secretion of 
IL-1β from PBMCs where Caspase 1 has been inhibited by capase 1 inhibitor (0.325 µM) 
are shown in Table 7. Inhibition of Caspase 1 had only minimal effects on PCP-induced 
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IL-1β secretion. Figure 4D (representative data from F317), shows 3, 4, and 5 fold increases 
when PBMCs are exposed to 1, 2.5 and 5 µM PCP in the absence of C1 inhibitor. When the 
inhibitor is present, these same PCP exposures result in 1.6, 5.1, and 3.2 fold increases in 
IL-1β secretion. These results suggest that Caspase 1 may play a small role in PCP’s ability 
to stimulate secretion of IL-1β.
DISCUSSION
Both PCP and DDT are found at significant level in human blood samples, with PCP being 
as high as 5 µM (Cline et al., 1989) and DDT as high as 260 nM (Koepke et al., 2004). PCP 
exposure has been associated with kidney cancer, lymphoma, and myeloma (Demers et al., 
2006) while DDT exposure is linked to increased incidences of liver, pancreatic, breast, and 
testicular cancers as well as leukemia (Eskanazi et al., 2009; Cohn et al., 2007; Snedeker & 
Stapleton, 2009). Studies have shown that the tumor binding (Hurd et al., 2012; Hurd-Brown 
et al., 2013) and lysing function (Reed et al., 2004; Nnodu and Whalen, 2008) of human NK 
lymphocytes as well as their expression of important cell surface proteins (Hurd et al., 2012; 
Hurd-Brown et al., 2013) is decreased by ex vivo exposure to PCP and DDT. IL-1β in its 
role as a pro-inflammatory cytokine is a master regulator of the immune response (Sahoo et. 
al, 2011; Dinarello, 1996). Dysregulation of its levels can lead to loss of immune 
competency (decreased levels) or chronic inflammation (increased levels) (Dinarello 1996; 
Braddock and Quinn, 2004; Dinarello, 2004). The current study examined whether PCP 
and/or DDT exposure altered secretion of this important cytokine from increasingly complex 
preparations of human immune cells and results indicated that both compounds were able to 
increase IL-1β secretion dependent on length and concentration of the exposure.
The immune cell preparations used in this study ranged from a preparation that was 
predominantly NK lymphocytes to PBMCs which were a combination of lymphocytes and 
monocytes. Additionally, a preparation of T and NK lymphocytes (MD-PBPMCs) was also 
examined. When these 3 cell preparations were exposed to PCP there was no major effect on 
the viability of the immune cells, which indicated that the effects seen on IL-1β secretion 
were not due cell death. NK cells tended to show decreases in IL-1β secretion as the highest 
concentration of PCP (5 µM) and increases at lower concentrations (the specific 
concentration at which increases were seen varied among donors). However, when the more 
complex preparations (MD-PBMCs and PBMCs) were exposed to PCP there were increases 
in IL-1β secretion induced by the higher exposure concentrations after 24 h. For instance all 
donors tested showed increases at the 5 µM concentration after 24 h in MD-PBMCs and at 
the 5–1 µM concentrations in PBMCs. In PBMCs, concentrations as low as 0.1 µM caused 
significant increases (approximately 2 fold) in secretion after either 24 or 48 h of exposure 
in cells from all donors and the lowest concentration examined (0.05 µM) also caused 
significant increases in 3 of the 4 donors at one or more length of exposure. The highest fold 
increase seen with PCP exposure was 13 fold after a 24 h exposure to 5 µM PCP in PBMCs. 
Thus, all cell preparations tested showed alterations in IL-1β secretion in response to PCP 
exposures. However, preparations with T cells (MD-PBMCs) and with monocytes (PBMCs) 
had a different pattern of response than was seen with NK cells. This suggests that the more 
complex milieu of cells, that more closely approximates physiological conditions, responds 
to a wide range of PCP exposures by increasing secretion of the pro-inflammatory IL-1β.
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DDT exposures caused the same general effect in all three cell preparations. NK cells, MD-
PBMCs, and PBMCs from all donors showed significant increases in IL-1β secretion with 
exposures to one or more PCP concentration at one or more length of incubation. Increases 
tended to be approximately 2 fold and usually persisted out to 6 days of exposure. Increases 
most commonly occurred at the 2.5 µM exposure, but in some donors occurred at the lowest 
concentration of 0.025 µM.
Signaling pathways involved in regulating the release of IL-1β from immune cells include 
Caspase I, NFκB and MAPKs (ERK1/2, p38, and JNK) (Lopez-Castejon & Brough, 2011; 
Gaestel et al., 2009). PCP caused very robust increases in IL-1β secretion from PBMCs and 
thus, this PCP-induced secretion was examined for the involvement of the above mentioned 
signaling pathways. The data indicated that Caspase 1, NFκB, and JNK played little to no 
role in the ability of PCP to stimulate IL-1β release from immune cells, while both ERK1/2 
and p38 MAPK pathways appeared to be needed for the effect. For example a 4 fold 
increase in IL-1β secretion stimulated by 1 µM PCP was dropped to 1.6 fold when the 
ERK1/2 pathway was inhibited with PD98059. Likewise inhibition of the p38 pathway 
resulted in a loss of PCP-induced IL-1β secretion. Previous studies on exposure to PCP have 
shown an association of PCP exposures with a number of cancers (Demers et al., 2006; 
Cooper & Jones, 2008) and increased IL-1β has been shown to promote cancer development 
(Balkwill & Mantovani 2001; Coussens & Werb, 2002). Thus, if PCP has effects on IL-1β 
secretion in exposed individuals, similar to those seen with a complex ex vivo system, the 
increased risk of cancer might be at least in part due to its capacity to increase IL-1β levels.
Both PCP and DDT showed variations in their effects on IL-1β secretion (specific lengths 
and concentrations of exposure) that was donor dependent. The concept of personalized 
treatment of a number of diseases, most especially cancer (Madureira & de Mello, 2014) has 
begun to evolve. The results from this study indicate that there may individualized responses 
to these environmental toxicants, which may be important in assessing risk for a variety of 
conditions. Additionally, these result indicate that both PCP and DDT may have the capacity 
to induce “sterile inflammation” (a term used to describe inflammation occurring in the 
absence of a microorganism) (Chen & Nunez, 2010). The results of the current study 
indicate that concentrations of PCP and DDT that have been shown to occur in human blood 
(Cline et al., 1989; Uhl et al., 1986; Koepke et al., 2004; Trejo-Acevedo et al., 2009) lead to 
elevation of IL-1β ex vivo. Such “sterile inflammation” could worsen multiple sclerosis and 
rheumatoid arthritis (Lucas & Hohlfeld, 1995; Choy & Panayi, 2001) as well as lead to 
enhanced tumor development and progression (Lewis & Varghese, 2006;Smith & Kang, 
2013). The results of the current study indicate that decreasing the levels of exposure to 
these contaminants, resulting in accompanying decreases in blood levels, may be important 
in preventing potential increases in the pro-inflammatory cytokine, IL-1β.
In summary, both PCP and DDT cause increased secretion of the seminal pro-inflammatory 
cytokine IL-1β from increasingly reconstituted preparations of immune cells. This increased 
secretion occurs at varying concentrations of the toxicants over several lengths of exposure 
with the effects varying among donors. The PCP- induced increases in IL-1β secretion (from 
PBMCs) are largely independent of Caspase 1, NFκB, and JNK signaling activity, but 
appear to require the p38 MAPK pathway.
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Effects of 24 h, 48 h and 6 day exposures to PCP on IL-1β secretion from MD-PBMCs, and 
PBMCs. A) MD-PBMCs exposed to 0.05–5µM PCP (donor F241); B) PBMCs exposed to 
0.05–5µM PCP (donor F197)
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Effects of 24 h, 48 h and 6 day exposures to DDT on IL-1β secretion from MD-PBMCs, and 
PBMCs. A) MD-PBMCs exposed to 0.025–2.5µM DDT (donor F245); B) PBMCs exposed 
to 0.025–2.5µM DDT (donor F229).
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Effects of 24 h exposure to 0.5, 1, and 2.5 µM PCP on IL-1β secretion from PBMCs pre-
treated with selective enzyme inhibitors. A) NFκB Inhibitor (BAY 11-7085) (donor F317); 
B) MEK Inhibitor (PD98059) (donor F320); C) p38 Inhibitor (SB202190) (donor F3179; D) 
JNK inhibitor (B178D3) (donor F317; E.) Caspase 1(F317)
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Table 1
Effects of 24 h, 48 h, 6 day exposures to PCP on IL1β secretion from NK cells.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[PCP]
µM
KB188 KB192 KB194 KB196
0 73345±6628 108±5 207±30 132±44
0.05 56693±8398 93±5* 203±33 202±32
0.1 84823±7309 109±7 167±25 215±40
0.25 86243±5274 72±6 * 149±16 145±9
0.5 64243±4225 99±10 191±18 170±16
1 86475±1945 50±10* 153±21 132±15
2.5 97751±2472* 25±1* 81±25* 50±16
5 81954±1158 42±2* 0±5* 0±6*
48 h Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[PCP]
µM
KB188 KB192 KB194 KB196
0 66929±3421 154±4 237±16 229±35
0.05 76262±3303* 160±17 254±21 278±60
0.1 73359±1549 168±5* 248±26 290±17
0.25 80972±389* 207±8* 227±7 312±43
0.5 83574±2710* 243±18* 308±12* 219±22
1 84026±1231* 202±15* 273±11* 233±20
2.5 83703±5892* 67±2* 169±38 41±15*
5 74004±2972* 50±1 * 7±4* 0±2*
6day Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[PCP]
µM
KB188 KB192 KB194 KB196
0 5087±248 176±9 116±3 134±122
0.05 6837±282* 110±5* 200±22* 207±210*
0.1 4636±379 148±6* 187±5* 229±237*
0.25 5447±86 178±2 183±6* 157±154
0.5 5252±328 221±18* 160±3* 188±194
1 5594±253 210±5* 165±8* 164±160
2.5 6054±300* 82±5* 80±8* 58±49*
5 5137±142 76±2* 0±5* 0±0
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05
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Table 2
Effects of 24 h, 48 h, 6 day exposures to PCP on IL-1β secretion from MD-PBMCS.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[PCP]
µM
F209 F239 F241 F243
0 647±26 5139±355 978±80 660±28
0.05 879±267 6705±1112 3260±276* 521±107
0.1 851±61* 5031±256 2591±377* 546±21*
0.25 740±16* 7998±1992 3107±150* 431±45*
0.5 594±37 4731±188 2723±262* 767±101
1 872±21* 4764±394 2938±369* 619±37
2.5 1258±42* 7401±700* 1373±93* 806±90
5 1115±53* 9151±751* 2446±109* 1291±247*
48 h Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[PCP]
µM
F209 F239 F241 F243
0 2791±128 2523±325 1220±123 427±192
0.05 2509±583 4506±917 2029±574 1445±1694
0.1 1936±87* 4478±2370 2842±266* 770±281
0.25 2233±115* 3590±437* 2868±45* 411±19
0.5 2824±169 6251±389* 8385±857* 1591±475*
1 1727±83* 4996±1204 1224±221 1126±198*
2.5 1494±53* 4223±30* 3295±463* 1226±48*
5 1654±72* 4884±265* 3306±32* 1349±57*
6day Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[PCP]
µM
F209 F239 F241 F243
0 1559±68 2862±185 450±43 471±33
0.05 1338±176 2769±274 604±401 641±145
0.1 1554±35 3102±185 1149±188* 669±95
0.25 1820±56* 2412±157* 910±194* 571±97
0.5 2111±75* 2979±108 1914±199* 1100±106*
1 1982±13* 3618±243* 2577±867 1310±166*
2.5 1960±97* 4042±390* 1441±98* 2290±369*
5 1934±80* 4275±526* 2252±115* 3631±14*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05
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Table 3
Effects of 24 h, 48 h, 6 day exposures to PCP on IL-1β secretion from PBMCs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[PCP]
µM
F197 F211 F214 F238
0 2267±199 1707±58 915±135 417±26
0.05 2051±187 1683±354 1054±245 472±10
0.1 2482±340 2950±73* 838±74 524±21*
0.25 3058±11* 2269±287 948±56 445±43
0.5 1352±101* 1878±22* 1021±31 448±16
1 3058±171* 2011±99* 1249±63* 493±10*
2.5 4247±474* 3850±311* 1887±7* 620±42*
5 6175±196* 3169±279* 2407±205* 5541±22*
48 h Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[PCP]
µM
F197 F211 F214 F238
0 1310±315 2083±73 612±50 729±24
0.05 1532±202 3305±114* 1317±221* 978±182
0.1 2324±239* 2956±401 1128±87* 1126±16*
0.25 2426±530* 2807±87* 2544±184* 1820±42*
0.5 2495±215* 4093±280* 3201±301* 1091±105*
1 2019±281* 3870±87* 2360±207* 968±82*
2.5 1894±161 4374±312* 3225±148* 1308±101*
5 3343±222* 4907±88* 3438±378* 1357±50*
6day Interleukin 1 b eta secreted in ng/mL (mean±S.D.)
[PCP]
µM
F197 F211 F214 F238
0 1208±151 1074±118 879±23 736±220
0.05 1867±93* 1620±132* 1126±144 638±71
0.1 2180±214* 1243±51 1162±20* 797±132
0.25 2513±259* 1326±31 2674±15* 715±49
0.5 2458±151* 1581±55* 3034±180* 1102±51
1 5422±380* 1773±46* 2918±85* 2069±183*
2.5 4898±250* 1750±153* 3209±154* 2297±159*
5 8105±97* 1693±134* 4456±94* 3191±140*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05
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Table 4
Effects of 24 h, 48 h, 6 day exposures to DDT on IL1β secretion from NK cells.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DDT]
µM
KB188 KB192 KB194 KB196
0 39769±5081 104±23 332±37 251±19
0.025 58589±10393 137±39 155±19* 208±3
0.05 43000±11533 261±14* 375±32 194±5*
0.1 45256±5198 98±18 329±65 188±1*
0.25 50051±5757 77±4 301±15 199±12*
0.5 41692±8240 112±63 331±8 213±9
1 44051±9959 95±16 333±76 208±24
2.5 32795±10276 282±24* 807±35* 370±10*
48 h Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DDT]
µM
KB188 KB192 KB194 KB196
0 54415±1594 116±7 1027±75 303±21
0.025 79000±3581* 148±20 623±43* 241±45
0.05 73414±5891* 87±3* 723±30* 365±24*
0.1 66929±2278* 125±17 878±37 342±37
0.25 59975±3274 163±12* 1160±13 325±53
0.5 51317±2598 95±6* 598±28* 296±39
1 79610±4146* 118±31 669±47* 157±84
2.5 44585±737* 265±13* 1178±81 132±42*
6day Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DDT]
µM
KB188 KB192 KB194 KB196
0 74828±2802 94±6 621±12 182±8
0.025 82052±2853* 137±18* 610±40 200±4*
0.05 73649±1074 143±0.7* 394±29* 193±23
0.1 69711±1219 139±0.7* 598±14 220±9*
0.25 57525±1531* 158±13* 550±47 154±50
0.5 78921±2280 105±3 470±49* 175±7
1 73588±2799 103±8 484±6* 183±4
2.5 67169±2843* 142±7* 379±13* 169±7
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05













Martin and Whalen Page 21
Table 5
Effects of 24 h, 48 h, 6 day exposures to DDT on IL-1β secretion from MD-PBMCs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DDT]
µM
F245 F281 F287 F288
0 1020±380 2333±764 1846±239 1326±54
0.025 1016±218 2295±518 1171±296* 1452±134
0.05 821±39 1984±484 941±174* 1944±1045
0.1 795±27 1836±43 1030±52* 1340±157
0.25 661±201 2601±952 917±176* 1157±39*
0.5 802±56 2667±511 648±98* 1305±9
1 955±119 2727±109 732±59* 1876±217*
2.5 2158±183* 4951±128* 699±29* 2676±202*
48 h Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DDT]
µM
F245 F281 F287 F288
0 2769±874 2697±359 653±116 1409±139
0.025 2151±707 2017±416 688±80 1309±56
0.05 1793±249 2496±191 547±241 1283±109
0.1 1753±205 2322±283 778±250 1120±86*
0.25 2387±318 2572±139 724±81 1246±178
0.5 2346±558 2544±334 1240±334 1289±63
1 1915±944 2607±750 647±12 1508±173
2.5 6338±514* 5919±1239* 1372±69* 3243±82*
6day Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DDT]
µM
F245 F281 F287 F288
0 1015±142 1883±77 518±7 561±13
0.025 3035±495* 2765±139* 736±406 666±56
0.05 1826±210* 3340±157* 510±10 488±47
0.1 1241±117 2105±262 944±356 589±51
0.25 1665±180* 2870±67* 533±107 595±68
0.5 1266±161 2123±85* 486±42 675±58
1 1365±87* 2815±225* 1112±35* 738±37*
2.5 2607±247* 3815±96* 495±6* 1185±43*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05
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Table 6
Effects of 24 h, 48 h, 6 day exposures to DDT on IL-1β secretion from PBMCs.
24 h Interleukin 1 beta secreted in pg/mL (mean±S.D.)
[DDT]
µM
F197 F201 F220 F229
0 2113±195 3233±155 1930±44 4177±121
0.025 3008±348* 3486±261 1901±66 4303±336
0.05 1300±156* 2668±189* 1887±87 3419±73*
0.1 2238±136 3304±234 2002±205 3847±78*
0.25 1081±83* 2562±111* 1945±100 3478±76*
0.5 1300±31* 3028±130 1800±157 3471±146*
1 1425±219* 3033±813 2351±176* 3639±180*
2.5 3477±79* 4295±590 3162±66* 6216±64*
48 h Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DDT]
µM
F197 F201 F220 F229
0 2257±211 3028±354 2242±303 4182±312
0.025 3118±723 2462±299 1833±296 3919±335
0.05 3239±301 1114±80* 2030±184 3699±176
0.1 2342±804 2878±194 1985±105 2096±1272
0.25 2739±329 3597±1022 2667±446 2951±182*
0.5 2494±102 2960±55 2773±120 3487±346
1 2242±185 3312±166 2091±79 3607±1702
2.5 3438-277* 4844±185* 3530±229* 7263±92*
6day Interleukin 1 beta secreted in ng/mL (mean±S.D.)
[DDT]
µM
F197 F201 F220 F229
0 1463±104 1653±61 3621±268 7276±187
0.025 2327±709 1884±116 2693±413* 7061±172
0.05 1851±162* 2056±168* 3020±58 5632±157*
0.1 2442±691 1438±226 1629±932 6428±43*
0.25 1884±1120 1916±43* 3052±50 6592±142*
0.5 1179±115* 1889±155 3027±64 6575±269*
1 1966±1117 2169±65* 3132±201 5925±164*
2.5 1851±293 2534±57* 4433±109* 10383±162*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant change in secretion compared to control cells (cells treated with vehicle alone), p<0.05
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